In a recent study, published in PNAS, researchers developed an ingenious point-of-care diagnostic method using synthetic peptide biomarkers and immunoassays. The method was capable of detecting and quantifying colorectal cancer and thrombosis biomarkers directly from unpurified urine.
With additional development, the test is proposed to be applicable for detection of a host of noncommunicable diseases, without the requirement for expensive equipment or medically trained personnel. The cost of manufacturing a simple lateral flow assay device was estimated to be less than $2.60 per test.
Genscript peptide news
With additional development, the test is proposed to be applicable for detection of a host of noncommunicable diseases, without the requirement for expensive equipment or medically trained personnel. The cost of manufacturing a simple lateral flow assay device was estimated to be less than $2.60 per test.
(Today 12:28 PM)Genscriptlorraine Wrote: In a recent study, published in PNAS, researchers developed an ingenious point-of-care diagnostic method using synthetic peptide biomarkers and immunoassays. The method was capable of detecting and quantifying colorectal cancer and thrombosis biomarkers directly from unpurified urine.
With additional development, the test is proposed to be applicable for detection of a host of noncommunicable diseases, without the requirement for expensive equipment or medically trained personnel. The cost of manufacturing a simple lateral flow assay device was estimated to be less than $2.60 per test.
Genscript peptide news